Current Therapeutic Approaches for Early-Stage HER2-Positive Breast Cancer

Current Therapeutic Approaches for Early-Stage HER2-Positive Breast Cancer: Aligning Practice With Expert Consensus

Wednesday, July 10, 2019 in Hopewell, Virginia
Live Meeting -- John Randolph Medical Center, 8:00 AM ET
3rd Floor, Main Hospital, Family Center


  • Overview of systemic therapy options for HER2-positive EBC
  • Expert recommendations for neoadjuvant therapy options in HER2-positive EBC
  • Latest insights on adjuvant and extended adjuvant therapy options and strategies
  • Synergistic mechanisms of action (MoAs) of pertuzumab with trastuzumab
  • Unique MoA of neratinib to irreversibly inhibit multiple ErbB receptor tyrosine kinases at the intracellular level
  • Applying the evidence and approved therapy approaches to practice
    • Node-negative and small tumors, node-positive with or without large tumors, HER2-positive/hormone receptor–positive EBC, age considerations, considering patient preferences and goals
    • Response after neoadjuvant therapy and surgery
    • Patients in whom adjuvant trastuzumab with pertuzumab followed by extended adjuvant therapy with neratinib is the optimal choice
  • Patient education, consultation, and collaboration
  • Managing diarrhea and other symptoms associated with treatment
  • Ongoing translational research on HER2 mutations and other biomarkers



Goal Statement
The goal of this activity is to improve the knowledge and competence of physicians and other healthcare providers in treating patients with HER2-positive early-stage breast cancer.

Target Audience 
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with HER2-positive early-stage breast cancer.

Learning Objectives

  • Plan optimal adjuvant and extended adjuvant treatment strategies for patients with HER2- positive early-stage breast cancer based on available data and expert recommendations
  • Integrate new combination regimens into adjuvant treatment strategies for patients with HER2-positive early-stage breast cancer
  • Manage adverse events effectively in patients with early-stage breast cancer receiving adjuvant therapy based on available data and recommendations
  • Discuss the available treatment options including current approvals and indications to patients to help them be proactive, knowledgeable participants in their care


Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.